Navigation Links
January Market Jitters Fails to Derail Biotech
Date:2/1/2008

SAN FRANCISCO, Feb. 1 /PRNewswire/ -- Fears that the economy is not only heading towards a recession but is also rapidly weakening had investors in a skittish mood during January. However, biotech held steady with the Burrill Biotech Select Index closing unchanged well ahead of the NASDAQ, which posted a January loss of 9.9%, and the Dow, which closed down 4.6%.

"Healthcare is usually able to ride out extremely volatile capital markets with less damage because they are viewed as 'safe' stocks in recession periods," said G. Steven Burrill, CEO of Burrill & Company a San Francisco based global leader in life sciences whose principal activities are in Private Equity, Venture Capital, Merchant Banking and Media, "and biotech, on a relative basis, performed well in January." Helping the cause was the buzz created around the JPMorgan's 26th Annual Healthcare Conference, which continues to set records for attendance during the four day San Francisco-based event. Many of the 300-plus companies, which presented at the event were reporting updated clinical and year end results ... and the mood was quite optimistic.

Most notable was Pharmasset, whose shares surged to close the month up 87%. Early in January the company announced positive data from a short-term Phase I study on its hepatitis C candidate, R7128. The four-week trial assessed two doses of Pharmasset's R7128 in combination with the standard of care, Pegasys plus Copegus, in 50 chronically infected patients who hadn't received prior treatment. Pharmasset said 85% of patients given the higher dose, 1,500 milligrams, and 30% at the lower 500 milligram dose had undetectable levels of the virus after four weeks. In comparison, only 10% of patients on the placebo, which was standard of care alone, achieved undetectable levels of the virus.

Pharmasset was the only bright spot amongst a sea of decliners in the Burrill Mid-Cap Biotech Index group as shares of these companies got dragged down with
'/>"/>

SOURCE Burrill & Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Correction to Press Release Dated January 31, 2008: Inverness Medical Innovations to Participate at 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference on February 5, 2008
2. Abaxis to Report Third Quarter Fiscal 2008 Financial Results Thursday, January 31, 2008
3. Exelixis Announces January 31 Webcast of Presentation at the 2008 Wachovia Healthcare Conference
4. Hologic, Inc. to Release First Quarter Fiscal 2008 Operating Results Thursday, January 31st Before Market Opens
5. Bristol-Myers Squibb to Announce Results for the Fourth Quarter and Full Year of 2007 on January 31
6. ARCA Discovery, Inc. to Present at 26th Annual JPMorgan Healthcare Conference on January 8, 2008
7. Exelixis Announces January 10 Webcast of Presentation at the 26th Annual JPMorgan Healthcare Conference
8. Inverness Medical Innovations to Participate at JP Morgan Healthcare Conference on January 8, 2008
9. LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern
10. BioForm Medical to Present at the 2008 JPMorgan Healthcare Conference on January 7, 2008
11. Stryker to Host Conference Call on January 23, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 28, 2014 Research and Markets ... Biology Market 2014-2018" report to their offering. ... term synthetic biology covers the designing and engineering of ... as the redesigning of natural biological systems that provide ... a form of extreme genetic engineering because it not ...
(Date:7/28/2014)...   Propeller Health , the FDA-cleared digital health ... Brad Towle as Senior Vice President, Business ... the company,s sales growth, customer acquisition and program expansion. ... his past role in the development of accountable care ... pivotal time in the industry," said David Van ...
(Date:7/28/2014)... COLLEGE STATION, Texas , July 28, 2014   ... will be a 177-key, 4-star boutique hotel in the heart of ... , Texas.  Photo - http://photos.prnewswire.com/prnh/20140725/130455 ... first hotel within ATLAS , The ... of standard rooms and suites, a sleek restaurant and bar, a ...
(Date:7/25/2014)... 25, 2014 Amgen (NASDAQ: AMGN ... a $0.61 per share dividend for the third quarter ... 5, 2014, to all stockholders of record as of ... About Amgen Amgen is committed to unlocking ... illnesses by discovering, developing, manufacturing and delivering innovative human ...
Breaking Biology Technology:Global Synthetic Biology Market 2014-2018 2Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 2Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 3Texas' Biocorridor Announces the Atlas Hotel, Centerpiece of Mixed Use Community for Biotech Industry 4Amgen Announces 2014 Third Quarter Dividend 2Amgen Announces 2014 Third Quarter Dividend 3
... LESS Instrumentation Is Selected for Industry Leader LESS Panel ... 29 Cambridge Endo, a pioneer in the rapidly ... or SPA) market, is pleased to announce that its ... leaders selected to be on a LESS panel at ...
... Laboratory InstrumentsMENLO PARK, Calif. and NORWOOD, Mass., Jan. ... today jointly announced that Advanced Instruments Inc. has ... The two companies further announced their intention ... generation of laboratory instruments for osmolality measurement, incorporating ...
... N.J., Jan. 29 Amicus Therapeutics (Nasdaq: ... 2008 financial results after the regular close of markets ... be followed by a live conference call and webcast ... investors may access the conference call at 5 p.m. ...
Cached Biology Technology:Cleveland Clinic Selects Laparoendoscopic Single-Site Surgery (LESS) as One of the Top Ten Innovations of 2009 2Advanced Instruments Makes Strategic Investment in Cantimer, Inc. 2Amicus Therapeutics Announces Fourth Quarter and Year End 2008 Financial Results Release Date 2
(Date:7/28/2014)... ago, MIT professor John Essigmann and colleagues from the University ... They thought if they could induce the virus to mutate ... out a strategy that our immune system uses against ... which caused HIV to mutate at an enhanced rate, as ... in a small clinical trial reported in 2011. In a ...
(Date:7/28/2014)... Eight of the top 10 U.S. cities that have ... public inconveniences as frequent road closures, overwhelmed storm drains ... a new NOAA technical report. , This nuisance flooding, ... three U.S. coasts, between 300 and 925 percent since ... Nuisance Flood Frequency Changes around the United States, also ...
(Date:7/28/2014)... MANHATTAN, Kansas He calls himself the bug hunter, ... that can only be found and identified with special ... at the Kansas State Veterinary Diagnostic Laboratory at Kansas ... his discoveries, porcine enterovirus G, which is an important ... a virus in cells, but didn,t know what it ...
Breaking Biology News(10 mins):Forced mutations doom HIV 2Forced mutations doom HIV 3Forced mutations doom HIV 4NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 2NOAA: 'Nuisance flooding' an increasing problem as coastal sea levels rise 3Researcher using next-generation sequencing to rapidly identify pathogens 2Researcher using next-generation sequencing to rapidly identify pathogens 3
... CORVALLIS, Ore. Researchers at Oregon State University ... the collapse of oyster seed production at a commercial ... to a level considered by the owners to be ... that elevated seawater carbon dioxide (CO2) levels, resulting in ...
... Mass. Copper the stuff of pennies and tea ... can turn carbon dioxide into hydrocarbon fuels with relatively little ... copper acts as a strong catalyst, setting off an electrochemical ... methane or methanol. Various researchers around the world have ...
... CO, USA -- April 10, 2012 -- HUNT Biosciences ... advance the clinical use of protein biomarkers, with an ... prediction of cardiovascular events such as strokes, heart attacks, ... samples and clinical data from HUNT Biosciences using SomaLogic,s ...
Cached Biology News:Ocean acidification linked to larval oyster failure 2Ocean acidification linked to larval oyster failure 3Hybrid copper-gold nanoparticles convert CO2 2Hybrid copper-gold nanoparticles convert CO2 3
Human Ig Lambda-chain, clone ICO-16, Monoclonal Antibody...
Rabbit polyclonal to Warfarin ( Abpromise for all tested applications). Antigen: Chemical / Small Molecule conjugated to KLH...
WNV Core Antibody...
... Rabbit polyclonal to FANCM ( Abpromise ... Antigen: Synthetic peptide derived from within ... FANCM. (Note: the amino acid sequence ... as ab27787 .) ...
Biology Products: